Protean Aktiesparfond Norden Divests Entire Novo Nordisk Stake

Protean Aktiesparfond Norden, a fund managed by Richard Bråse, has sold all its shares in Novo Nordisk due to persistent issues with generic competition in the US. The fund previously held a significant stake in the Danish pharmaceutical giant, citing its growth prospects and profitability profile. Novo Nordisk shares had declined due to prescription issues in the US, which the fund believed would improve if capacity constraints were resolved. The fund now manages over 1.4 billion Swedish kronor.